Table 3.
Subgroup analysis with univariate Cox regression analysis of overall survival between HAS and SRC after PSM.
| Subgroup | SRC | HAS | p-value | ||||
|---|---|---|---|---|---|---|---|
| n total | n event (%) | HR (95% CI) | n total | n event (%) | HR (95% CI) | ||
| Gender | |||||||
| Male | 158 | 54 (34.2) | 1 (Ref) | 38 | 12 (31.6) | 1.43 (0.76–2.69) | 0.263 |
| Female | 42 | 14 (33.3) | 1 (Ref) | 12 | 4 (33.3) | 1.3 (0.43–3.99) | 0.643 |
| Age ≥ 60 years old | |||||||
| No | 85 | 29 (34.1) | 1 (Ref) | 22 | 5 (22.7) | 0.99 (0.38–2.57) | 0.979 |
| Yes | 115 | 39 (33.9) | 1 (Ref) | 28 | 11 (39.3) | 1.77 (0.9–3.48) | 0.098 |
| Neoadjuvant chemotherapy | |||||||
| Yes | 16 | 6 (37.5) | 1 (Ref) | 4 | 1 (25) | 0.74 (0.09–6.18) | 0.782 |
| No | 184 | 62 (33.7) | 1 (Ref) | 46 | 15 (32.6) | 1.45 (0.82–2.56) | 0.201 |
| BMI ≥ 24 | |||||||
| Yes | 88 | 32 (36.4) | 1 (Ref) | 25 | 9 (36) | 1.49 (0.71–3.14) | 0.297 |
| No | 112 | 36 (32.1) | 1 (Ref) | 25 | 7 (28) | 1.26 (0.56–2.85) | 0.580 |
| Location | |||||||
| Proximal | 52 | 14 (26.9) | 1 (Ref) | 14 | 6 (42.9) | 3.05 (1.13–8.2) | 0.027 |
| Middle | 68 | 21 (30.9) | 1 (Ref) | 17 | 5 (29.4) | 1.56 (0.58–4.18) | 0.381 |
| Distal | 80 | 33 (41.2) | 1 (Ref) | 19 | 5 (26.3) | 0.7 (0.27–1.8) | 0.456 |
| Tumor size ≥ 4 cm | |||||||
| Yes | 108 | 42 (38.9) | 1 (Ref) | 28 | 9 (32.1) | 1.14 (0.55–2.35) | 0.723 |
| No | 92 | 26 (28.3) | 1 (Ref) | 22 | 7 (31.8) | 1.9 (0.81–4.43) | 0.137 |
| T stage | |||||||
| T 1a & 1b | 20 | 1 (5) | 1 (Ref) | 5 | 0 (0) | 0 (0–Inf) | 0.999 |
| T 2 | 38 | 15 (39.5) | 1 (Ref) | 10 | 1 (10) | 0.41 (0.05–3.15) | 0.393 |
| T 3 | 78 | 32 (41) | 1 (Ref) | 19 | 4 (21.1) | 0.7 (0.25–2) | 0.511 |
| T 4a & 4b | 64 | 20 (31.2) | 1 (Ref) | 16 | 11 (68.8) | 3.69 (1.75–7.79) | 0.001 |
| N stage | |||||||
| N 0 | 70 | 8 (11.4) | 1 (Ref) | 16 | 1 (6.2) | 0.6 (0.07–4.83) | 0.633 |
| N 1 | 32 | 11 (34.4) | 1 (Ref) | 8 | 1 (12.5) | 0.86 (0.11–6.97) | 0.887 |
| N 2 | 48 | 19 (39.6) | 1 (Ref) | 12 | 5 (41.7) | 1.66 (0.61–4.48) | 0.318 |
| N 3a &3b | 50 | 30 (60) | 1 (Ref) | 14 | 9 (64.3) | 2.54 (1.14–5.65) | 0.022 |
| Lymph nodes examined ≥16 | |||||||
| Yes | 42 | 15 (35.7) | 1 (Ref) | 9 | 1 (11.1) | 0.36 (0.05–2.75) | 0.325 |
| No | 158 | 53 (33.5) | 1 (Ref) | 41 | 15 (36.6) | 1.73 (0.97–3.09) | 0.062 |
| Perineural invasion | |||||||
| Yes | 58 | 29 (50) | 1 (Ref) | 14 | 4 (28.6) | 0.78 (0.27–2.22) | 0.639 |
| No | 142 | 39 (27.5) | 1 (Ref) | 36 | 12 (33.3) | 1.91 (0.99–3.67) | 0.052 |
| Vascular invasion | |||||||
| Yes | 59 | 23 (39) | 1 (Ref) | 16 | 8 (50) | 2.1 (0.92–4.78) | 0.078 |
| No | 141 | 45 (31.9) | 1 (Ref) | 34 | 8 (23.5) | 1.06 (0.5–2.25) | 0.888 |
| Cancer nodules | |||||||
| Yes | 24 | 12 (50) | 1 (Ref) | 6 | 5 (83.3) | 3.52 (1.16–10.72) | 0.026 |
| No | 176 | 56 (31.8) | 1 (Ref) | 44 | 11 (25) | 1.17 (0.61–2.24) | 0.636 |
| CEA > 5.0 μg/L | |||||||
| No | 173 | 58 (33.5) | 1 (Ref) | 42 | 11 (26.2) | 1.1 (0.58–2.11) | 0.766 |
| Yes | 27 | 10 (37) | 1 (Ref) | 8 | 5 (62.5) | 3.61 (1.07–12.16) | 0.038 |
| CA199 > 37.0 U/ml | |||||||
| No | 182 | 62 (34.1) | 1 (Ref) | 45 | 12 (26.7) | 1.14 (0.61–2.12) | 0.681 |
| Yes | 18 | 6 (33.3) | 1 (Ref) | 5 | 4 (80) | 4.69 (1.24–17.78) | 0.023 |
| CA724 > 10.0 U/ml | |||||||
| No | 181 | 59 (32.6) | 1 (Ref) | 45 | 14 (31.1) | 1.57 (0.87–2.82) | 0.134 |
| Yes | 19 | 9 (47.4) | 1 (Ref) | 5 | 2 (40) | 0.71 (0.15–3.28) | 0.659 |
AFP, Alpha fetoprotein; BMI, Body mass index; CA Carbohydrate antigen; CEA, Carcinoembryonic antigen; HAS, Hepatoid adenocarcinoma of the stomach; HR, Hazard ratio; SRC, Signet ring cell carcinoma.